Aleksandra Żołnierek
Research Subjects
Aleksandra Żołnierek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dominika Gacka
Szpital Morski Im. PCK, Gdynia, Poland
5 shared publications - Katarzyna Gondek
PIM MSWiA w Warszawie, Warsaw, Poland
5 shared publications - Magdalena Fidelis
Szpital Morski Im. PCK, Gdynia, Poland
5 shared publications - Maksymilian Czarnota
PCK Maritime Hospital, 1 Powstania Styczniowego Street, 81-519 Gdynia, Poland
5 shared publications - Maria Wojcieszek
Medical University of Warsaw, Warsaw, Poland
5 shared publications - Noor Alhuda Al-Karawi
PIM MSWiA w Warszawie, Warsaw, Poland
5 shared publications
Latest Publications
- Open Access
PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) are established maintenance therapies in epithelial ovarian cancer (EOC). Although considered relatively safe, their impact on renal function remains unclear. Increases in serum creatinine (SCr) are frequently observed during treatment, but the clinical significance of these changes is uncertain. We conducted a systematic review and meta-analysis to assess the risk of renal adverse events associated with PARPis in randomized controlled trials (RCTs). Methods: PubMed/MEDLINE, Embase, and the Cochrane Library were searched for phase II–III, placebo-controlled RCTs published through 30 June 2025. Eligible studies enrolled patients with ovarian cancer receiving maintenance monotherapy with olaparib, niraparib, rucaparib, or fuzuloparib and reported renal adverse events. The primary endpoint was creatinine increase (all grades). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models according to heterogeneity. Results: Nine high-quality RCTs comprising 2578 patients met the inclusion criteria. PARPi therapy was associated with a significantly increased risk of creatinine elevation compared with placebo (OR 5.04; 95% CI 3.51–7.24; p < 0.001). Heterogeneity was moderate (I2 = 31.7%). High-grade renal adverse events (≥grade 3) were rare (<1%) and could not be reliably pooled. No significant publication bias was detected. Conclusions: PARP inhibitors significantly increase the likelihood of SCr elevation in EOC; however, severe nephrotoxicity appears uncommon in RCTs. Observed SCr increases may partly reflect inhibition of renal tubular creatinine transport rather than true reductions in glomerular filtration. Careful renal monitoring and prospective studies incorporating direct GFR assessment are warranted.
Open AccessPARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) are established maintenance therapies in epithelial ovarian cancer (EOC). Although considered relatively safe, their impact on renal function remains unclear. Increases in serum creatinine (SCr) are frequently observed during treatment, but the clinical significance of these changes is uncertain. We conducted a systematic review and meta-analysis to assess the risk of renal adverse events associated with PARPis in randomized controlled trials (RCTs). Methods: PubMed/MEDLINE, Embase, and the Cochrane Library were searched for phase II–III, placebo-controlled RCTs published through 30 June 2025. Eligible studies enrolled patients with ovarian cancer receiving maintenance monotherapy with olaparib, niraparib, rucaparib, or fuzuloparib and reported renal adverse events. The primary endpoint was creatinine increase (all grades). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models according to heterogeneity. Results: Nine high-quality RCTs comprising 2578 patients met the inclusion criteria. PARPi therapy was associated with a significantly increased risk of creatinine elevation compared with placebo (OR 5.04; 95% CI 3.51–7.24; p < 0.001). Heterogeneity was moderate (I2 = 31.7%). High-grade renal adverse events (≥grade 3) were rare (<1%) and could not be reliably pooled. No significant publication bias was detected. Conclusions: PARP inhibitors significantly increase the likelihood of SCr elevation in EOC; however, severe nephrotoxicity appears uncommon in RCTs. Observed SCr increases may partly reflect inhibition of renal tubular creatinine transport rather than true reductions in glomerular filtration. Careful renal monitoring and prospective studies incorporating direct GFR assessment are warranted.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
NIPAH VIRUS: CLINICAL PERSPECTIVES ON AN EMERGING PRIORITY PATHOGEN
The emergence of zoonotic viral diseases has significantly impacted public health, the global economy, and societal structures in recent years. The World Health Organization's 2024 updated R&D Blueprint report identifies infectious agents posing the greatest epidemiological threats. Among them is the Nipah virus (NiV), a highly lethal paramyxovirus naturally harboured by fruit bats, which typically causes severe respiratory distress and encephalitis in humans. Moreover, the NiV exhibits the capacity to infect a wide range of mammalian species, including livestock and domestic pets. The secretions and excretions of these animals can potentially serve as sources of human infection. This presents both a direct health risk and an indirect one, due to losses in agriculture and associated economic consequences. After the first outbreak in Malaysia (1998–1999), in addition to decontamination measures, mass culling of pigs was carried out. Although Malaysia has been declared free of NiV infection, new cases continue to emerge almost annually in Bangladesh and India, with the most recent reported in 2025. Given the current scale of human migration, the global nature of food transportation, and other facets of globalization, it is imperative to prepare for the potential spread of the disease of a magnitude similar to COVID-19. To date, no targeted therapies or vaccines have been approved. Given this situation, the primary objective of the present work is to raise awareness among clinicians regarding the characteristics and pathogenicity of NiV, as well as the practical aspects related to the recognition, diagnosis, and treatment of the infection.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessNIPAH VIRUS: CLINICAL PERSPECTIVES ON AN EMERGING PRIORITY PATHOGEN
The emergence of zoonotic viral diseases has significantly impacted public health, the global economy, and societal structures in recent years. The World Health Organization's 2024 updated R&D Blueprint report identifies infectious agents posing the greatest epidemiological threats. Among them is the Nipah virus (NiV), a highly lethal paramyxovirus naturally harboured by fruit bats, which typically causes severe respiratory distress and encephalitis in humans. Moreover, the NiV exhibits the capacity to infect a wide range of mammalian species, including livestock and domestic pets. The secretions and excretions of these animals can potentially serve as sources of human infection. This presents both a direct health risk and an indirect one, due to losses in agriculture and associated economic consequences. After the first outbreak in Malaysia (1998–1999), in addition to decontamination measures, mass culling of pigs was carried out. Although Malaysia has been declared free of NiV infection, new cases continue to emerge almost annually in Bangladesh and India, with the most recent reported in 2025. Given the current scale of human migration, the global nature of food transportation, and other facets of globalization, it is imperative to prepare for the potential spread of the disease of a magnitude similar to COVID-19. To date, no targeted therapies or vaccines have been approved. Given this situation, the primary objective of the present work is to raise awareness among clinicians regarding the characteristics and pathogenicity of NiV, as well as the practical aspects related to the recognition, diagnosis, and treatment of the infection.
- Open Access
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60689
Autism Spectrum Disorder in ICD-11: Diagnostic, Therapeutic and Identity - Related Implications of the Discontinuation of Asperger's Syndrome as a Separate Diagnosis
The reclassification of Asperger’s syndrome within DSM-5 (2013) and ICD-11 (2019) marked a pivotal moment in the diagnostic landscape of neurodevelopmental disorders. After three decades of being recognized as a distinct clinical entity, Asperger’s syndrome was merged into the broader autism spectrum disorder (ASD) category, triggering extensive debate over diagnostic precision, social identity, and clinical consequences. This review synthesizes evidence on the evolution of diagnostic criteria, with a focus on historical milestones (Kanner, Asperger, Wing) that shaped the conceptualization of autism and Asperger’s syndrome across successive DSM and ICD editions. A structured literature search (PubMed, Scopus, Google Scholar; 2005–2024) identified 92 peer-reviewed articles meeting inclusion criteria (English or Polish language, human studies, and clear reference to diagnostic transitions and their psychosocial or clinical impact). Special attention is given to the effects of reclassification on individuals’ identity, the risk of diagnostic loss—especially in those with mild or atypical profiles—and the evolving terminology debate. Findings indicate that approximately 10–15% of individuals previously diagnosed with Asperger’s syndrome no longer meet ASD criteria under DSM-5 and ICD-11, raising concerns about service access and psychological well-being. The review also discusses challenges in distinguishing ASD from personality disorders, the diagnostic implications of camouflaging behaviors, and future research directions aimed at refining assessment tools and supporting neurodivergent identity.
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60689
Open AccessAutism Spectrum Disorder in ICD-11: Diagnostic, Therapeutic and Identity - Related Implications of the Discontinuation of Asperger's Syndrome as a Separate Diagnosis
The reclassification of Asperger’s syndrome within DSM-5 (2013) and ICD-11 (2019) marked a pivotal moment in the diagnostic landscape of neurodevelopmental disorders. After three decades of being recognized as a distinct clinical entity, Asperger’s syndrome was merged into the broader autism spectrum disorder (ASD) category, triggering extensive debate over diagnostic precision, social identity, and clinical consequences. This review synthesizes evidence on the evolution of diagnostic criteria, with a focus on historical milestones (Kanner, Asperger, Wing) that shaped the conceptualization of autism and Asperger’s syndrome across successive DSM and ICD editions. A structured literature search (PubMed, Scopus, Google Scholar; 2005–2024) identified 92 peer-reviewed articles meeting inclusion criteria (English or Polish language, human studies, and clear reference to diagnostic transitions and their psychosocial or clinical impact). Special attention is given to the effects of reclassification on individuals’ identity, the risk of diagnostic loss—especially in those with mild or atypical profiles—and the evolving terminology debate. Findings indicate that approximately 10–15% of individuals previously diagnosed with Asperger’s syndrome no longer meet ASD criteria under DSM-5 and ICD-11, raising concerns about service access and psychological well-being. The review also discusses challenges in distinguishing ASD from personality disorders, the diagnostic implications of camouflaging behaviors, and future research directions aimed at refining assessment tools and supporting neurodivergent identity.
- Open Access
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60681
Understanding Postpartum Psychosis: Current Perspectives and Clinical Implications
Postpartum psychosis (PPP) is a rare but severe psychiatric condition that typically emerges within the first two weeks after childbirth, requiring immediate clinical intervention due to risks of suicide and infanticide. Despite its severity, PPP remains under-recognized in major diagnostic classifications such as the DSM-5 and ICD-10, complicating diagnosis and legal considerations. This review synthesizes current knowledge on PPP, including its epidemiology, multifactorial etiology, clinical presentation, and management strategies. Risk factors span genetic vulnerability, hormonal and immune dysregulation, sleep disruption, and psychosocial stressors. Diagnosis is often delayed due to stigma and lack of specific screening tools. Treatment includes a stepwise pharmacological approach using benzodiazepines, antipsychotics, lithium, and electroconvulsive therapy (ECT) for refractory cases, alongside psychosocial interventions. Lithium maintenance therapy has demonstrated significant efficacy in relapse prevention, while medication safety during lactation remains a key clinical concern. The review underscores the urgent need for standardized diagnostic criteria, greater public and professional awareness, and further research into the biological mechanisms underlying PPP. Timely detection and coordinated care can significantly improve outcomes for both mother and child.
- 6 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 83, 60681
Open AccessUnderstanding Postpartum Psychosis: Current Perspectives and Clinical Implications
Postpartum psychosis (PPP) is a rare but severe psychiatric condition that typically emerges within the first two weeks after childbirth, requiring immediate clinical intervention due to risks of suicide and infanticide. Despite its severity, PPP remains under-recognized in major diagnostic classifications such as the DSM-5 and ICD-10, complicating diagnosis and legal considerations. This review synthesizes current knowledge on PPP, including its epidemiology, multifactorial etiology, clinical presentation, and management strategies. Risk factors span genetic vulnerability, hormonal and immune dysregulation, sleep disruption, and psychosocial stressors. Diagnosis is often delayed due to stigma and lack of specific screening tools. Treatment includes a stepwise pharmacological approach using benzodiazepines, antipsychotics, lithium, and electroconvulsive therapy (ECT) for refractory cases, alongside psychosocial interventions. Lithium maintenance therapy has demonstrated significant efficacy in relapse prevention, while medication safety during lactation remains a key clinical concern. The review underscores the urgent need for standardized diagnostic criteria, greater public and professional awareness, and further research into the biological mechanisms underlying PPP. Timely detection and coordinated care can significantly improve outcomes for both mother and child.
- Open Access
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60580
Impact of Dietary Factors on Thyroid Function and Disorders
Thyroid health is intricately linked to nutritional status, as multiple micronutrients and dietary components modulate hormone biosynthesis, metabolism, and immune function. The increasing global prevalence of autoimmune thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, underscores the need to examine the influence of modifiable dietary factors on thyroid pathophysiology. This narrative review aimed to evaluate current evidence on the role of nutrition—especially micronutrients such as iodine, selenium, iron, zinc, and vitamin D—in thyroid function and autoimmunity. A structured literature search was conducted using PubMed and Scopus to identify relevant human studies published between January 2002 and March 2025. A total of forty-one peer-reviewed articles were selected based on predefined inclusion criteria and assessed for scientific rigor and relevance. The evidence confirms the critical involvement of iodine and selenium in thyroid hormone synthesis and immune modulation, while iron and zinc were found to support enzymatic activity and endocrine stability. Vitamin D emerged as a potential immunoregulatory agent in autoimmune thyroid disease. Furthermore, certain macronutrients—including high-quality proteins, fiber, and omega-3 fatty acids—as well as dietary patterns such as the Mediterranean diet, were associated with favorable thyroid outcomes. Conversely, the intake of goitrogenic foods and soy isoflavones may necessitate caution in predisposed individuals. These findings highlight the relevance of individualized, evidence-based nutritional strategies as adjunctive approaches in the prevention and clinical management of thyroid disorders.
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60580
Open AccessImpact of Dietary Factors on Thyroid Function and Disorders
Thyroid health is intricately linked to nutritional status, as multiple micronutrients and dietary components modulate hormone biosynthesis, metabolism, and immune function. The increasing global prevalence of autoimmune thyroid disorders, particularly Hashimoto’s thyroiditis and Graves’ disease, underscores the need to examine the influence of modifiable dietary factors on thyroid pathophysiology. This narrative review aimed to evaluate current evidence on the role of nutrition—especially micronutrients such as iodine, selenium, iron, zinc, and vitamin D—in thyroid function and autoimmunity. A structured literature search was conducted using PubMed and Scopus to identify relevant human studies published between January 2002 and March 2025. A total of forty-one peer-reviewed articles were selected based on predefined inclusion criteria and assessed for scientific rigor and relevance. The evidence confirms the critical involvement of iodine and selenium in thyroid hormone synthesis and immune modulation, while iron and zinc were found to support enzymatic activity and endocrine stability. Vitamin D emerged as a potential immunoregulatory agent in autoimmune thyroid disease. Furthermore, certain macronutrients—including high-quality proteins, fiber, and omega-3 fatty acids—as well as dietary patterns such as the Mediterranean diet, were associated with favorable thyroid outcomes. Conversely, the intake of goitrogenic foods and soy isoflavones may necessitate caution in predisposed individuals. These findings highlight the relevance of individualized, evidence-based nutritional strategies as adjunctive approaches in the prevention and clinical management of thyroid disorders.
- Open Access
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60525
Gene Therapy and Down Syndrome: Can the future of Medicine bring a breakthrough?
Down syndrome (DS), or trisomy 21, is the most common chromosomal disorder, characterized by intellectual disability, congenital anomalies, and an increased risk of neurodegenerative diseases. This review synthesizes current knowledge on the etiology, clinical presentation, and modern therapeutic strategies for DS, including early intervention, medical management, and psychosocial support. Particular emphasis is placed on the revolutionary potential of CRISPR-Cas gene-editing technology as a tool for future treatment strategies. Drawing upon findings from many scientific publications, the article discusses the mechanism of CRISPR, its current medical applications, and its experimental use in silencing the extra chromosome 21 or correcting DS-associated genes. Technical, ethical, and delivery-related limitations are explored, alongside speculative but promising research directions, including base editing, prime editing, and cerebral organoids. The article concludes with a reflection on whether societal perceptions of genetic diversity should evolve alongside scientific innovation, highlighting that the greatest breakthrough may come not from altering genomes, but from fostering inclusion and understanding.
- 30 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60525
Open AccessGene Therapy and Down Syndrome: Can the future of Medicine bring a breakthrough?
Down syndrome (DS), or trisomy 21, is the most common chromosomal disorder, characterized by intellectual disability, congenital anomalies, and an increased risk of neurodegenerative diseases. This review synthesizes current knowledge on the etiology, clinical presentation, and modern therapeutic strategies for DS, including early intervention, medical management, and psychosocial support. Particular emphasis is placed on the revolutionary potential of CRISPR-Cas gene-editing technology as a tool for future treatment strategies. Drawing upon findings from many scientific publications, the article discusses the mechanism of CRISPR, its current medical applications, and its experimental use in silencing the extra chromosome 21 or correcting DS-associated genes. Technical, ethical, and delivery-related limitations are explored, alongside speculative but promising research directions, including base editing, prime editing, and cerebral organoids. The article concludes with a reflection on whether societal perceptions of genetic diversity should evolve alongside scientific innovation, highlighting that the greatest breakthrough may come not from altering genomes, but from fostering inclusion and understanding.